Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
In recognition of the critical role played by the CCTG throughout her professional career, Dr. Frances Shepherd has provided support for an annual travel award to recognize excellence in clinical trials and translational research within CCTG research projects.
2019 New Investigator Clinical Trials Course
Mark your calendars for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.
The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of this three-day course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
On Monday May 27th CCTG launched a new look for our website.
The objectives for the new look:
Strategic design principles were applied to enable our multiple target audiences to find the relevant content for them. The CCTG site has historically been a tool for the CCTG trial management audience and is now also enabled to communicate to patients and families, our partners and donors.
Website target audiences:
Dr. Wassim Kassouf is a urologic oncologist working at the McGill University Health Center, the CCTG BL12 study chair and is currently a member of the clinical trials committee in genito-urinary diseases. Dr. Kassouf maintains that the BL13 trial will help evaluate whether combination therapy improves the disease control locally but also in terms of distant metastases and survival.
MAC26 (S1706) trial has been centrally activated, this is a Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
CCTG Spring meeting travel expenses are reimbursed only by submitting a properly completed travel expense claim form. This form, accompanied by original documents, should be submitted to CCTG Group Administrator’s Office no later than 30 June 2019.
Dr. Khalil Sultanem is a Radiation Oncologist working at the Jewish General Hospital at McGill University. He is involved in the Head and Neck disease site committee at CCTG and is the Co-Chair of the HN9 study. Dr. Sultanem believes the HN9 study is a unique and innovative study because it provides a possibility to replace chemotherapy, which is toxic, with immunotherapy.
